Australia Legal Cannabis Market By Source (Hemp (Hemp CBD Oil, Supplements and Industrial Hemp) and Marijuana (Flower, Oil and Tinctures)), By Derivative (CBD (Cannabidiol), THC (Tetrahydrocannabinol) and Others), By Application (Medical (Chronic Pain, Cancer, Anxiety, Arthritis, Epilepsy, PTSD and Others), Recreational (Legalized in ACT and Restricted elsewhere) and Industrial), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Report Overview

The Australia Legal Cannabis Market size is expected to be worth around US$ 3012.4 Million by 2035 from US$ 879.6 Million in 2025, growing at a CAGR of 13.1% during the forecast period 2026-2035.

Increasing acceptance of cannabinoid-based therapies accelerates the Australia Medical Cannabis market as patients and healthcare providers recognize its potential in managing chronic and complex conditions. Physicians prescribe medical cannabis for severe chronic pain in cancer patients, where THC and CBD combinations reduce opioid dependency and improve quality of life.

These products support epilepsy treatment by decreasing seizure frequency in refractory cases through CBD-dominant formulations. Neurologists apply medical cannabis to alleviate spasticity in multiple sclerosis patients, enhancing mobility and daily functioning.

Palliative care specialists utilize it to control nausea and vomiting induced by chemotherapy, allowing better tolerance of treatment regimens. Patients with anxiety disorders and PTSD benefit from balanced THC-CBD products that promote relaxation without significant psychoactive effects.

Manufacturers pursue opportunities to develop novel delivery methods such as oral oils, capsules, and vaporizers that improve bioavailability and patient adherence in long-term therapies. Developers advance research into new indications like inflammatory bowel disease and neurodegenerative disorders, broadening the therapeutic scope of medical cannabis.

These advancements facilitate integration with conventional treatments for multimodal pain management in fibromyalgia and arthritis. Opportunities emerge in personalized formulations based on patient genetics and symptom profiles.

Recent trends emphasize high-CBD low-THC products for pediatric epilepsy and non-psychoactive applications, alongside rigorous clinical trials that validate efficacy and safety. Companies focus on quality assurance and standardized dosing to build physician confidence and expand mainstream medical adoption.

Key Takeaways

• In 2025, the market generated a revenue of US$ 879.6 Million, with a CAGR of 13.1%, and is expected to reach US$ 3012.4 Million by the year 2035.
• The source segment is divided into hemp and marijuana, with hemp taking the lead with a market share of 54.1%.
• Considering derivative, the market is divided into CBD (cannabidiol), THC (tetrahydrocannabinol) and others. Among these, cbd held a significant share of 56.1%.
• Furthermore, concerning the application segment, the market is segregated into medical, recreational and industrial. The medical sector stands out as the dominant player, holding the largest revenue share of 76.4% in the market.

Source Analysis

Hemp accounted for 54.1% of growth within source and dominate the Australia legal cannabis market due to regulatory acceptance and expanding cultivation programs. Australian regulators permit hemp cultivation with very low THC content, which supports production of cannabidiol extracts and industrial hemp materials.

Farmers increasingly allocate land for hemp because the crop offers diverse applications in pharmaceuticals, nutraceuticals, textiles, and food products. Segment growth is expected to accelerate as the Australian hemp industry continues to scale under licensing frameworks. Hemp-based cannabidiol products gain traction in medical formulations for pain, anxiety, and sleep disorders.

Domestic production also reduces reliance on imported cannabis raw materials. Industry reports indicate steady growth in licensed hemp cultivation areas across several Australian states. Demand for hemp derivatives is anticipated to rise as healthcare practitioners recommend plant-based therapeutic alternatives. Expanding research initiatives into hemp-based compounds further reinforce its leading role in the market.

Derivative Analysis

CBD accounted for 56.1% of growth within derivatives and dominate due to strong clinical interest and patient preference for non-intoxicating therapeutic compounds. Healthcare providers increasingly prescribe cannabidiol-based treatments under Australia’s Special Access Scheme and Authorized Prescriber programs.

Government data from the Therapeutic Goods Administration show tens of thousands of medical cannabis approvals issued annually, with CBD-dominant products representing a large share of prescriptions. Segment growth is projected to strengthen as more physicians gain familiarity with cannabinoid therapies.

Patients favor CBD because it addresses symptoms without producing psychoactive effects associated with THC. Pharmaceutical companies expand product portfolios that include oils, capsules, and oral sprays containing cannabidiol.

Clinical trials in Australia continue to evaluate CBD for epilepsy, chronic pain, and neurological conditions. Demand is likely to expand as regulatory pathways simplify access to low-dose CBD medicines. Increasing awareness among healthcare professionals and patients further supports sustained adoption.

Application Analysis

Medical accounted for 76.4% of growth within applications and dominate the Australia legal cannabis market due to strong regulatory oversight and growing therapeutic acceptance. Chronic pain represents the most frequently reported condition treated with medical cannabis in Australia.

Therapeutic Goods Administration data indicate that chronic pain accounts for a majority of medical cannabis prescriptions issued through national access schemes. Physicians increasingly incorporate cannabinoid therapies into treatment plans when conventional medications provide limited relief.

Segment growth is expected to accelerate as clinical evidence supporting cannabis-based treatments continues to expand. Patients seek alternatives that reduce dependence on opioid analgesics and other high-risk drugs.

Healthcare providers emphasize controlled dosing and monitored treatment protocols to improve safety outcomes. Demand is anticipated to increase as patient awareness and physician training programs continue to expand across Australia.

Key Market Segments

By Source

• Hemp
  • Hemp CBD Oil
  • Supplements
  • Industrial Hemp
• Marijuana
  • Flower
  • Oil
  • Tinctures

By Derivative

• CBD (Cannabidiol)
• THC (Tetrahydrocannabinol)
• Others

By Application

• Medical
  • Chronic Pain
  • Cancer
  • Anxiety
  • Arthritis
  • Epilepsy
  • PTSD
  • Others
• Recreational
  • Legalized in ACT
  • Restricted elsewhere
• Industrial

Drivers

Rising patient access through Special Access Scheme approvals is driving the market. The Australia legal cannabis market, focused primarily on medicinal use, continues to expand due to substantial increases in approvals under the Therapeutic Goods Administration’s Special Access Scheme Category B pathway. Official TGA data indicate that SAS-B approvals reached 177,737 in 2024. This figure advanced to 224,462 during 2025, reflecting a 26 percent increase from the previous year.

The growth demonstrates enhanced prescriber engagement and greater patient demand for cannabis-based therapies across various conditions. Approvals in the first half of 2025 specifically totaled 113,692, doubling from 55,489 in the first half of 2022. Such progression highlights the pathway’s role in facilitating access to unapproved products where registered alternatives remain scarce.

Practitioners increasingly utilize the scheme for chronic pain, mental health, and other therapeutic needs. The consistent upward trajectory in approvals during 2023-2025 supports supply chain activation among licensed entities. This driver reinforces clinical integration and sustains market momentum nationwide.

Restraints

Pricing pressure on cannabis flower products is restraining the market. The market encounters moderation from significant declines in cannabis flower pricing, which affects producer profitability and investment capacity. Flower prices fell from approximately AUD 6 per gram in 2023 to lower levels by 2025. This contraction impacts smaller cultivators particularly, as reduced margins limit operational sustainability.

Pricing dynamics arise from increased domestic supply and competitive importation. Retail and wholesale segments experience downward pressure on revenue per unit sold. The trend constrains reinvestment in cultivation infrastructure and quality enhancements.

Producers must adapt strategies to maintain viability amid commoditization risks. The restraint influences overall market stability during the 2023-2025 period. Supply adjustments reflect challenges in balancing volume growth with economic returns. This factor tempers the pace of sector advancement despite rising patient numbers.

Opportunities

Introduction of women’s health-focused cannabis product lines is creating growth opportunities. Targeted product development for specific demographic needs presents notable prospects for differentiated expansion. ECS Botanics announced plans in December 2025 to launch the AVANI AVA portfolio in Australia during 2026.

The range encompasses pessaries, dried flower, topical creams, and capsules designed for conditions commonly reported by female patients via the SAS-B pathway. More than 40 percent of medicinal cannabis prescriptions in Australia now involve female patients. This demographic shift creates demand for tailored formulations addressing women’s health concerns.

The initiative leverages integrated cultivation and formulation capabilities to engage prescribers and pharmacists effectively. Opportunities emerge for enhanced patient adherence through specialized delivery formats.

The development aligns with evolving prescriber preferences for condition-specific options. Such innovation fosters deeper market penetration and brand loyalty. This opportunity supports long-term diversification and therapeutic relevance within the sector.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic conditions influence the Australia legal cannabis market through consumer spending, investment flows, and operating costs across cultivation and retail segments. Inflation increases expenses for energy, greenhouse inputs, packaging, and compliance testing, which raises production costs for licensed operators.

Higher interest rates restrict access to growth capital and slow expansion of cultivation facilities and dispensary networks. Geopolitical tensions affect international trade in cannabis genetics, extraction equipment, and pharmaceutical processing systems, creating procurement uncertainty.

Current US tariffs on specialized cultivation technologies and processing machinery increase equipment costs for Australian companies that source from US suppliers. These pressures can delay infrastructure upgrades and limit short-term profitability for emerging producers.

At the same time, operators invest in local manufacturing, domestic supply chains, and energy-efficient production models to manage risk. Expanding regulatory acceptance and increasing consumer awareness continue to support steady and confident long-term market growth.

Latest Trends

Strategic partnerships for inhalation device distribution are driving the market.

Collaborative agreements enhance product accessibility and innovation in delivery methods during the recent period. Bioxyne, via its subsidiary Breathe Life Sciences, entered an exclusive agreement in November 2025 with Curaleaf International.

The partnership covers importation, manufacturing, and distribution of the Que Medical Inhalation Device in Australia. This marks the introduction of a certified inhalation technology to the local market. The arrangement expands options for precise dosing and rapid onset in medicinal applications.

Providers benefit from diversified administration routes beyond traditional oils and capsules. The trend reflects growing emphasis on patient convenience and efficacy. Partnerships facilitate technology transfer and local production capabilities. This development accelerates adoption of advanced devices in clinical settings. Overall, the 2025 agreement propels forward progress in product variety and market maturity.

Key Players Analysis

Leading companies in the Australia Legal Cannabis market pursue expansion through vertical integration, advanced cultivation technologies, and strong partnerships with medical clinics and pharmaceutical distributors. Firms focus on product diversification across CBD oils, THC formulations, and cannabinoid-based therapies while strengthening compliance with Therapeutic Goods Administration access pathways.

Cann Group Limited stands among the prominent industry participants and operates as an Australian medicinal cannabis grower and manufacturer engaged in breeding, cultivation, and supply of cannabis-derived treatments for domestic and export markets.

The company emphasizes research in plant genetics and controlled cultivation to deliver consistent medical-grade products for patients. Industry peers also expand physician education programs and telehealth collaborations to increase prescription volumes. These strategic initiatives strengthen market reach, improve clinical adoption, and support long-term revenue growth across Australia’s regulated cannabis ecosystem.

Top Key Players

• Vitura Health Limited (Dominant digital health and distribution platform)
• Little Green Pharma (LGP)
• Bioxyne
• Green Farmers (Biortica Agrimed)
• ECS Botanics
• Tasmanian Botanics
• Cann Group
• Zelira Therapeutics
• AusCann Group Holdings Ltd
• Bod Science
• Althea Group
• Incannex Healthcare

Recent Developments

• In January 2025, Biortica Agrimed expanded the cultivation footprint of its Green Farmers facilities in New South Wales and Victoria by roughly 12,000 square meters. The upgrade was carried out to strengthen local production capacity and maintain a stable domestic supply of medicinal cannabis, helping decrease dependence on imported pharmaceutical-grade flower.
• In April 2025, Software Effective Solutions Corp., operating as Medcana, expanded into the Australian market by obtaining licenses for the import and distribution of pharmaceutical-grade cannabis products, strengthening its global strategy to increase participation in regulated medical cannabis markets.

Report Scope